Johnson & Johnson (JNJ) Q1 2026 Earnings
How Did JNJ Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +7.73%.
Did JNJ Beat Earnings? Q1 2026 Results
Yes. Johnson & Johnson reported Q1 2026 earnings of $2.70 a share on Apr 14, 2026, beating the $2.68 consensus estimate by 0.8%. Revenue was $24.1B against a $23.6B estimate.
Johnson & Johnson opened 2026 on solid footing, posting first-quarter revenue of $24.06 billion, up 9.9% year-over-year and ahead of the $23.61 billion consensus estimate, while adjusted EPS of $2.70 edged past the $2.68 analyst expectation by 0.85%, extending the company's streak of consensus EPS beats to four consecutive quarters. The primary engine behind the top-line strength was the Innovative Medicine segment, where oncology delivered standout performance led by DARZALEX at $3.96 billion and CARVYKTI surging 62.1% to $597 million, more than offsetting a sharp 59.7% decline in STELARA as biosimilar competition intensified. MedTech contributed $8.64 billion, with Cardiovascular climbing 13.0% to $2.38 billion. Separately, the Board approved a 3.1% dividend increase to $1.34 per share quarterly, marking 64 consecutive years of dividend growth. Looking ahead, management raised its full-year 2026 guidance, now targeting revenue of $100.30 billion to $101.30 billion and adjusted diluted EPS of $11.45 to $11.65, reinforcing confidence in its path toward double-digit growth by decade's end.
- DARZALEX worldwide sales grew 22.5% to $3,964M driven by strong demand
- TREMFYA surged 68.3% to $1,608M as it captures share from biosimilar-eroded STELARA
- CARVYKTI grew 62.1% to $597M reflecting expanding cell therapy adoption
- RYBREVANT/LAZCLUZE grew 82.7% to $257M on new indication approvals
- CAPLYTA contributed $270M following Intra-Cellular Therapies acquisition in April 2025
- Electrophysiology, Abiomed, and Shockwave drove MedTech Cardiovascular growth of 13.0%
- Trauma products drove Orthopaedics growth in MedTech
- STELARA biosimilar competition resulted in 59.7% decline to $656M, approximately 920 bps drag on Innovative Medicine
- Favorable currency translation contributed 3.5% to worldwide sales growth
“Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact.”
Johnson & Johnson CEO, on the earnings call
What Was Johnson & Johnson's Outlook in Q1 2026?
Johnson & Johnson raised its full-year 2026 guidance. The company now expects estimated reported sales of $100.3B–$101.3B (midpoint $100.8B, 7.0% growth at midpoint), up from the prior January guidance of $100.0B–$101.0B (midpoint $100.5B). Adjusted operational sales growth is now expected at 5.6%–6.6% (midpoint 6.1%), up from 5.4%–6.4% (midpoint 5.9%). Adjusted EPS (diluted) is guided at $11.45–$11.65 (midpoint $11.55, 7.1% growth at midpoint), up from $11.43–$11.63 (midpoint $11.53). Adjusted operational EPS (diluted) is guided at $11.30–$11.50 (midpoint $11.40, 5.7% growth at midpoint). The company is solidifying its path to double-digit growth by the end of the decade. An Enterprise Business Review is planned for December 8, 2026.
JNJ YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $24.1B | $21.9B | +9.9% |
| Gross Profit | $16.0B | $14.5B | +9.8% |
| Net Income | $5.2B | $11.0B | −52.4% |
JNJ Revenue by Segment
JNJ Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.